Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT01002755 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Fatigue
Fever
Hypogammaglobulinemia
Lymphadenopathy
Lymphocytosis
Night Sweats
Paraproteinemia
Small Lymphocytic Lymphoma
Thrombocytopenia

Interventions

DRUG: Lenalidomide
BIOLOGICAL: Ofatumumab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]